Investigating how tumor metabolism and the immune environment affect liver cancer treatment
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC
This study is looking at how liver cancer works and how it responds to treatments, using mice to help find better ways to personalize care for patients with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10833543 on NIH RePORTER |
What this research studies
This research focuses on understanding the metabolic processes and immune environment of hepatocellular carcinoma (HCC), a type of liver cancer. By analyzing genetic mutations and their interactions, the study aims to develop more effective precision medicine approaches for HCC treatment. The researchers will create mouse models to mimic human HCC and assess how specific gene alterations influence tumor growth and response to therapies. This could lead to identifying biomarkers that predict treatment responses, ultimately improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hepatocellular carcinoma, particularly those with specific genetic mutations.
Not a fit: Patients with liver cancer who do not have the genetic mutations being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with hepatocellular carcinoma.
How similar studies have performed: Other research has shown promise in targeting tumor metabolism and immune responses in cancer treatment, indicating that this approach could be effective.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Monga, Satdarshan Singh — University of Pittsburgh at Pittsburgh
- Study coordinator: Monga, Satdarshan Singh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.